Randomized Controlled Double-blind Clinical Study on Yishen Gukang Recipe（益肾骨康方） Combined with Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Moderate to Severe Cancerous Pain with Kidney Deficiency and Blood Stasis Syndrome

SONG Hongli; YIN Yukun; ZHOU Lei; FENG Li

doi:10.13288/j.11-2166/r.2018.15.011

您当前的位置：

首页 >

文章列表页 >

Randomized Controlled Double-blind Clinical Study on Yishen Gukang Recipe（益肾骨康方） Combined with Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Moderate to Severe Cancerous Pain with Kidney Deficiency and Blood Stasis Syndrome

更新时间：2021-11-10

- Randomized Controlled Double-blind Clinical Study on Yishen Gukang Recipe（益肾骨康方） Combined with Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Moderate to Severe Cancerous Pain with Kidney Deficiency and Blood Stasis Syndrome
- Journal of Traditional Chinese Medicine Vol. 59, Issue 15, Pages: 1300-1304(2018)
- 作者机构：
  
  1. 中国中医科学院望京医院
  2. 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2018.15.011
  CLC： R730.5
- Published：2018
- 稿件说明：
移动端阅览
[1]宋洪丽,殷玉琨,周磊,冯利.益肾骨康方联合盐酸羟考酮缓释片治疗中重度癌性躯体痛肾虚血瘀证患者随机对照双盲临床研究[J].中医杂志,2018,59(15):1300-1304.

SONG Hongli, YIN Yukun, ZHOU Lei, et al. Randomized Controlled Double-blind Clinical Study on Yishen Gukang Recipe（益肾骨康方） Combined with Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Moderate to Severe Cancerous Pain with Kidney Deficiency and Blood Stasis Syndrome[J]. Journal of Traditional Chinese Medicine2018, 59(15): 1300-1304.
[1]宋洪丽,殷玉琨,周磊,冯利.益肾骨康方联合盐酸羟考酮缓释片治疗中重度癌性躯体痛肾虚血瘀证患者随机对照双盲临床研究[J].中医杂志,2018,59(15):1300-1304. DOI： 10.13288/j.11-2166/r.2018.15.011.

SONG Hongli, YIN Yukun, ZHOU Lei, et al. Randomized Controlled Double-blind Clinical Study on Yishen Gukang Recipe（益肾骨康方） Combined with Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Moderate to Severe Cancerous Pain with Kidney Deficiency and Blood Stasis Syndrome[J]. Journal of Traditional Chinese Medicine2018, 59(15): 1300-1304. DOI： 10.13288/j.11-2166/r.2018.15.011.

摘要

目的观察益肾骨康方联合盐酸羟考酮缓释片治疗中重度癌性躯体痛肾虚血瘀证患者的临床疗效及安全性。方法采用随机、对照、双盲的研究方法

将符合纳入标准的100例患者随机分为治疗组和对照组各50例

两组患者第1周给予盐酸羟考酮缓释片10 mg

每12 h口服1次;第2周治疗组给予盐酸羟考酮缓释片加益肾骨康方

对照组给予盐酸羟考酮缓释片加中药安慰剂

每日1剂

连续治疗7天。观察两组治疗前及治疗1、2周后疼痛数字评分法（NRS）评分、爆发痛次数、盐酸羟考酮缓释片用量

治疗1、2周后判定临床疗效

治疗期间观察不良事件发生情况。结果治疗2周后治疗组临床疗效总有效率为94.00%

显效率为70.00%

对照组分别为88.00%、40.00%

治疗组优于对照组（P<0.01）。治疗组治疗2周后NRS评分、盐酸羟考酮缓释片用量低于对照组（P<0.05）;两组治疗2周后较本组治疗1周后爆发痛次数降低（P<0.01）;治疗组不良事件发生情况少于对照组（P<0.05）。结论益肾骨康方联合盐酸羟考酮缓释片可减轻中重度癌性躯体痛肾虚血瘀证患者疼痛

减少阿片类药物用量

且不良反应少。

Abstract

Objective To observe the clinical efficacy and safety of Yishen Gukang Recipe（益肾骨康方） combined with oxycodone hydrochloride sustained-release tablets in the treatment of patients with moderate to severe cancer pain with kidney deficiency and blood stasis syndrome. Methods A randomized

controlled

double-blind study was conducted. Totally 100 patients who met the inclusion criteria were randomized into the treatment group and the control group

with 50 cases in each. Both groups received oxycodone hydrochloride sustained-release tablets 10 mg

oral administration once every 12 hours; in the second week

the treatment group was given oxycodone hydrochloride sustained-release tablets with Yishen Gukang Recipe

and the control group was given oxycodone hydrochloride sustained-release tablets with Chinese medicine placebo

one dose per day for 7 consecutive days. The numeric rating scale（ NRS）

the times of breakthrough pain

and the dose of oxycodone hydrochloride sustained-release tablets before and 1 and 2 week after treatment were observed in both groups. The clinical efficacy was determined after 1 and2 weeks of treatment

and the adverse events were observed during the treatment. Results After 2 weeks of treatment

the total effective rate was 94. 00%

and the markedly effective rate was 70. 00% in the treatment group. And the control group was 88. 00% and 40. 00% respectively. The treatment group was superior to the control group（ P <0. 01）. After 2 weeks of treatment

the NRS score and the dose of oxycodone hydrochloride sustained-release tablets were lower than those of the control group（ P < 0. 05）. After 2 weeks of treatment

the times of breakthrough pains decreased after 1 week of treatment（ P < 0. 01）. The incidence of adverse events in the treatment group was less than that in the control group（ P < 0. 05）. Conclusion Yishen Gukang Recipe combined with oxycodone hydrochloride sustained-release tablets can alleviate the pain of patients with moderate to severe cancerous pain with kidney deficiency and blood stasis syndrome

reduce the dosage of opioids

and have fewer adverse reactions.

关键词

Keywords

references

查看原文

Views

210

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Efficacy and Economic Evaluation of 1293 Non-Severe Adult Patients with Community-Acquired Pneumonia Treated by the Jiangsu Traditional Chinese Medicine Diagnosis and Treatment Protocol for Dominant Diseases：A Multicenter，Retrospective Real-World Cohort Study

Effect of Tongbian Decoction （通便汤） on the VAPB-PTPIP51 Complex and Autophagy of Interstitial Cells of Cajal in the Colon of Slow Transit Constipation Model Rats

LI Guolie's Experience in Treating Orthostatic Hypotension from the Perspective of "Raising the Clear and Directing the Turbid Downward"

Construction and Application of a Real-World Cohort of Community-Acquired Pneumonia Based on a Multimodal Large-Scale Traditional Chinese Medicine Big Data Platform

Differentiation and Treatment of Small Cell Lung Cancer from the Perspective of "Internal Wind in Hidden Circulation"

Related Author

No data

Related Institution

No data

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰